COVID 19 AND ITS EFFECTS ON HYPERTENSION FLUCTUATIONS IN IRAQI PATIENTS
Keywords:
COVID-19, ARDS, ICU, T2DAbstract
COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus, which more seriously affects patients of advanced ages and patients with immunodeficiency and chronic conditions, such as high blood pressure, and is of great importance in mortality from cardiovascular disease. vascular and cerebrovascular.
This paper aims to know the effects of COVID-19 on hypertension fluctuations in Iraqi patients
The retrospective study was conducted in one institution, different hospitals in Iraq, which is one of the main institutions for the care of patients with COVID-19 and 80 patients were collected and distributed into two groups, to 60 patients with hypertension and 20 patients as a control group,
It was concluded in this study that arterial hypertension is a clinical indicator of its severity in COVID-19 patients, and the study shows patients with hypertension have a higher mortality rate and also a higher likelihood of complications (severe COVID-19, ARDS, need for ICU and disease progression) which also leads to higher healthcare costs
References
Yan Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diab Res Care. 2020;8 (1): e001343. [PMC free article] [PubMed] [Google Scholar]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. LANCET. 2020;395(10229):1054–1062. [PMC free article] [PubMed] [Google Scholar]
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4): e21. [PMC free article] [PubMed] [Google Scholar]
The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing XueZaZhi. 2020; 41:145–151. [PubMed] [Google Scholar]
Liu J, Ma J, Wang J, et al. Comorbidity analysis according to sex and age in hypertension patients in China. Int J Med Sci. 2016; 13:99–107. [PMC free article] [PubMed] [Google Scholar]
Maronde RF, Chan LS, Larsen FJ, Strandberg LR, Laventurier MF, Sullivan SR. Underutilization of antihypertensive drugs and associated hospitalization. Med Care. 1989; 12:1159–1166. doi: 10.1097/00005650-198912000-00007. [PubMed] [CrossRef] [Google Scholar]
Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, et al. Patient risk factors for adverse drug events in hospitalized patients. Arch Intern Med. 1999;159 (21):2553–2560. doi: 10.1001/archinte.159.21.2553. [PubMed] [CrossRef] [Google Scholar]
Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52(8):1349–1354. doi: 10.1111/j.1532-5415.2004.52367. x. [PubMed] [CrossRef] [Google Scholar]
Rende P, Paletta L, Gallelli G, Raffaele G, Natale V, Brissa N, et al. Retrospective evaluation of adverse drug reactions induced by antihypertensive treatment. J Pharmacol Pharmacother. 2013;4 (Suppl 1): S47–S50. [PMC free article] [PubMed] [Google Scholar]
Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253 (22):3263–3268. doi:1001/jama.1985.03350460063022. [PubMed] [CrossRef] [Google Scholar]
Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension. 2001;38(4):809–814. doi: 10.1161/hy0901.091681. [PubMed] [CrossRef] [Google Scholar]
Butt T, Branch R, Beesley L, Martin U. Managing hypertension in the very elderly: effect of adverse drug reactions (ADRs) on achieving targets. J Hum Hypertens. 2010;24 (8):514–518. doi: 10.1038/jhh.2009.116. [PubMed] [CrossRef] [Google Scholar]
Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis, and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21 (2):147032032092689. [PMC free article] [PubMed] [Google Scholar]
Leiva SC, Espeche WG, Salazar MR. Arterial hypertension and the risk of severity and mortality of COVID-19. Eur Respir J. 2020;55(6):2001148. [PMC free article] [PubMed] [Google Scholar]
Kang SJ, Jung SI. Age-related morbidity and mortality among patients with COVID-19. Infect Chemother. 2020; 52 (2):154–164. [PMC free article] [PubMed] [Google Scholar]
Kang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations in covid-19. HEART. 2020;106 (15):1132–1141. heartjnl-2020-317056. [PMC free article] [PubMed] [Google Scholar]
Kreutz R, Algharably E, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020116(10):1688–1699. [PMC free article] [PubMed] [Google Scholar]
Liu B, Li M, Zhou Z, et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020; 111:102452. [PMC free article] [PubMed] [Google Scholar]
Loperena R, Van Beusecum JP, Itani HA, et al. Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin six and hydrogen peroxide. Cardiovasc Res. 2018; 114:1547–1563. [PMC free article] [PubMed] [Google Scholar]
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
